WallStSmart
GCTK

GlucoTrack Inc

NASDAQ: GCTK · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$0.70
+0.67% today

Updated 2026-06-03

Market cap
$3.79M
P/E ratio
0.10
P/S ratio
526.95x
EPS (TTM)
$6.27
Dividend yield
52W range
$0 – $14
Volume
5.9M

GlucoTrack Inc (GCTK) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-527.00%
ROA
-150.30%
Debt/equity
-0.03x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2009$-1.20M
2010$-2.79M
2011$-2.36M
2012$-2.77M
2013$-9.80M
2014$59775.00$2.98M100.00%6,034.90%4,986.07%
2015$143167.00$-5.84M68.64%3,251.69%-4,080.67%
2016$611689.00$-5.41M90.26%924.63%-884.39%
2017$589462.00$-10.33M76.21%1,794.15%-1,752.24%
2018$43488.00$-6.72M-119.75%15,035.41%-15,442.01%
2019$208000.00$-3.52M100.00%1,685.58%-1,690.38%
2020$70778.00$-2.70M-66.40%-4,425.10%-3,809.09%
2021$0.00$-4.07M
2022$0.00$-4.43M
2023$0.00$-7.10M
2024$0.00$-22.60M
2025$0.00$-19.39M

Frequently asked questions

How much free cash flow does GCTK generate?

GCTK produced $-15.34M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is GCTK's balance sheet healthy?

GCTK holds $7.38M in cash and equivalents against $231000.00 in long-term debt, on $2.83M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.